There are 51 resources available
Invited Discussant 1988MO, 1989MO and 1990MO
Presenter: Andrea Ardizzoni
Session: Mini oral session 1 - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Slides
Webcast
Invited Discussant LBA68 and LBA69
Presenter: Daniel Shao Weng Tan
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Slides
Webcast
Invited Discussant LBA70 and LBA71
Presenter: Yi-Long Wu
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Slides
Webcast
Invited Discussant LBA99 and LBA93
Presenter: Joachim Aerts
Session: Mini oral session 1 - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Slides
Webcast
1843MO - The effect of chronic psychological stress on the efficacy of first-line therapy of ICIs in advanced NSCLC (STRESS-LUNG-1 trial)
Presenter: Fang Wu
Session: Mini oral session - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
LBA58 - Pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage II-IIIA NSCLC patients (pts) in the phase III (Ph3) RATIONALE-315 trial
Presenter: Dongsheng Yue
Session: Mini oral session 2 - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
LBA69 - Aumolertinib plus apatinib versus aumolertinib as first-line treatment in patients with EGFR mutation positive locally advanced or metastatic non-small cell lung cancer (NSCLC): A randomized multicenter study
Presenter: Yi Hu
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1324MO - CNS outcomes of lazertinib vs gefitinib in EGFR-mutated advanced NSCLC: A LASER301 subset analysis
Presenter: Ross Soo
Session: Mini oral session 2 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
1262MO - Impact of a minimal versus CT-scan-based follow-up on patient-reported outcomes for completely resected non-small cell lung cancer (NSCLC) in phase III IFCT-0302 trial
Presenter: Guillaume Eberst
Session: Mini oral session 1 - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1317MO - Updated study results of pelcitoclax (APG-1252) combined with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC)
Presenter: Li Zhang
Session: Mini oral session 2 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast